Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
作者： Pavinder Kaur , Niklas Feldhahn , Bin Zhang , Daniel Trageser , Markus Müschen
关键词:
摘要: Background Ph-positive leukemias are caused by the aberrant fusion of BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which widely used treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds transiently imatinib therapy, we have mouse models test efficacy nilotinib against P190 form Bcr/Abl.
biomedcentral.com
springer.com
core.ac.uk
doaj.org参考文章(52)
Philipp le Coutre, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino, Carlo Gambacorti-Passerini, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. ,vol. 95, pp. 1758- 1766 ,(2000) , 10.1182/BLOOD.V95.5.1758.005A41_1758_1766
L S Steelman, S C Pohnert, J G Shelton, R A Franklin, F E Bertrand, J A McCubrey, JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. ,vol. 18, pp. 189- 218 ,(2004) , 10.1038/SJ.LEU.2403241
Jan Willem Voncken, Melvyn F. Greaves, John Groffen, Nora Heisterkamp, Paul K. Pattengale, Stephen Griffiths, Restricted Oncogenicity of BCR/ABL p190 in Transgenic Mice Cancer Research. ,vol. 52, pp. 4534- 4539 ,(1992)
Shanhai Xie, Hui Lin, Tong Sun, Ralph B Arlinghaus, Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. ,vol. 21, pp. 7137- 7146 ,(2002) , 10.1038/SJ.ONC.1205942
Wolf-K. Hofmann, Letetia C. Jones, Nathan A. Lemp, Sven de Vos, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann, H. Phillip Koeffler, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. ,vol. 99, pp. 1860- 1862 ,(2002) , 10.1182/BLOOD.V99.5.1860
S Mishra, B Zhang, J Groffen, N Heisterkamp, A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia. ,vol. 18, pp. 23- 28 ,(2004) , 10.1038/SJ.LEU.2403203
Shanhai Xie, Yan Wang, Jiaxin Liu, Tong Sun, Matthew B Wilson, Thomas E Smithgall, Ralph B Arlinghaus, Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. ,vol. 20, pp. 6188- 6195 ,(2001) , 10.1038/SJ.ONC.1204834
Nora Heisterkamp, Guido Jenster, Joanne ten Hoeve, Daniel Zovich, Paul K. Pattengale, John Groffen, Acute leukaemia in bcr/abl transgenic mice Nature. ,vol. 344, pp. 251- 253 ,(1990) , 10.1038/344251A0
Bin Zhang, John Groffen, Nora Heisterkamp, Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a Blood. ,vol. 106, pp. 1355- 1361 ,(2005) , 10.1182/BLOOD-2004-09-3655
Richard R. Hardy, Yue-Sheng Li, David Allman, Masanao Asano, Ming Gui, Kyoko Hayakawa, B-cell commitment, development and selection. Immunological Reviews. ,vol. 175, pp. 23- 32 ,(2000) , 10.1111/J.1600-065X.2000.IMR017517.X